Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Feb;39(2):339-348.
doi: 10.1007/s00345-019-03060-7. Epub 2020 Jan 2.

Navigating systemic therapy for metastatic castration-naïve prostate cancer

E M Kwan  1   2 , I A Thangasamy  3   4 , J Teh  3 , O Alghazo  3 , N J Sathianathen  3 , N Lawrentschuk  3   5 , A A Azad  6   7
Affiliations
Review

Navigating systemic therapy for metastatic castration-naïve prostate cancer

E M Kwan et al. World J Urol. 2021 Feb.

Abstract

Introduction: The last decade has seen a remarkable shift in the treatment landscape of advanced prostate cancer, none more so than in the management of metastatic castration-naïve disease.

Methods: This narrative review will examine existing and emerging evidence supporting systemic therapy use for metastatic castration-naïve prostate cancer (mCNPC) and provide guidance on the selection of these agents with respect to optimising patient outcomes.

Results: The addition of either docetaxel (chemohormonal approach) or an AR pathway inhibitor (abiraterone, enzalutamide or apalutamide) is a reasonable standard of care option for men commencing long-term ADT for mCNPC. While the issue of disease volume as a predictive biomarker for docetaxel benefit has previously been debated, recent data support consideration of upfront docetaxel in all patients, regardless of metastatic burden. Decisions regarding systemic treatment for men with mCNPC should be based on comprehensive consideration of disease, patient and logistical factors. Multiple novel therapeutics for mCNPC are currently under active investigation.

Conclusion: The introduction of potent systemic therapy earlier in the mCNPC disease course has resulted in dramatic improvements in clinical outcomes for patients. As the management of mCNPC continues to evolve, the future remains promising, with the expectation of ongoing improvements to patient outcomes and quality of life.

Keywords: Abiraterone; Androgen receptor pathway inhibitors; Apalutamide; Castration-naïve; Docetaxel; Enzalutamide; Hormone-sensitive; Metastatic prostate cancer.

PubMed Disclaimer

References

    1. American Cancer Society (2017) Cancer facts and figures 2017. American Cancer Society, Atlanta
    1. Huggins C, Hodges CV (1941) Studies on prostatic cancer I The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1(4):293
    1. Kunath F, Goebell PJ, Wullich B, Sikic D, Kahlmeyer A (2019) Timing of androgen deprivation monotherapy and combined treatments in castration-sensitive and castration-resistant prostate cancer: a narrative review. World J Urol. https://doi.org/10.1007/s00345-019-02704-y - DOI - PubMed
    1. Gravis G, Fizazi K, Joly F, Oudard S, Priou F, Esterni B et al (2013) Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol 14(2):149–58 - PubMed
    1. Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M et al (2015) Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 373(8):737–46 - PubMed - PMC

MeSH terms

Substances

LinkOut - more resources